Form 4: Nevro Corp. Director Sridhar Kosaraju Reports Disposal of Shares Following Merger with Globus Medical

Director Sridhar Kosaraju reports the disposal of Nevro Corp. shares due to the merger with Globus Medical, where each share was converted into $5.85 in cash.

Summary

• Sridhar Kosaraju, a director of Nevro Corp., filed a Form 4 to report changes in beneficial ownership of Nevro Corp. securities.
• The report is triggered by the merger between Nevro Corp. and Globus Medical, Inc., which became effective on April 3, 2025.
• As a result of the merger, Nevro Corp. became a wholly-owned subsidiary of Globus Medical.
• Each outstanding share of Nevro Corp. common stock was converted into the right to receive $5.85 in cash.
• Kosaraju disposed of 46,575 shares of common stock as a result of the merger.
• Outstanding restricted stock units and performance stock units were also converted into the right to receive cash based on the merger consideration.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as the merger provides a cash payout to shareholders, indicating a successful exit for investors. The filing itself is a routine administrative step following a significant corporate event.

Positives

• The merger provides Nevro Corp. shareholders with a cash payment of $5.85 per share.

Future Outlook

The document does not contain specific forward-looking statements beyond the completion of the merger.

Industry Context

This announcement reflects consolidation activity within the medical device industry, where companies seek to expand their product portfolios and market reach through mergers and acquisitions.

Comparison to Industry Standards

• Mergers in the medical device industry often involve a premium paid to the target company's shareholders.
• The $5.85 per share cash consideration should be compared to Nevro's trading price prior to the merger announcement to assess the premium received.
• Globus Medical's acquisition of Nevro is similar to other strategic acquisitions in the medical technology sector, such as Medtronic's acquisition of Mazor Robotics, where larger companies acquire innovative technologies or market share.

Stakeholder Impact

• Shareholders receive $5.85 per share in cash.
• Employees of Nevro Corp. become part of Globus Medical.
• The merger may impact the competitive landscape for suppliers and customers in the neuromodulation market.

Key Dates

Keywords

Merger, Globus Medical, Nevro Corp, Form 4, Beneficial Ownership, Sridhar Kosaraju